Opium (Opioid) Addiction - Pipeline Review, H1 2018

  • ID: 4479918
  • Drug Pipelines
  • 109 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Camurus AB
  • Indivior Plc
  • iX Biopharma Ltd
  • Novartis AG
  • Orexigen Therapeutics Inc
  • MORE
Opium (Opioid) Addiction - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Opium (Opioid) Addiction - Pipeline Review, H1 2018, provides an overview of the Opium (Opioid) Addiction (Central Nervous System) pipeline landscape.

Opioid Addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). This can lead to an inability for the body to stop pain because there are no endorphins to mask the pain initially. The degeneration of the nerve cells that reduce pain can lead to a physical dependence on opiates as an external supply source. Signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping and pain in the bones. The predisposing factors include age, a personal history of substance abuse, and family history of substance abuse, cigarette dependency and psychologic stress.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Opium (Opioid) Addiction - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opium (Opioid) Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 4, 6, 1, 14, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.

Opium (Opioid) Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Opium (Opioid) Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Opium (Opioid) Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Opium (Opioid) Addiction (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Opium (Opioid) Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Camurus AB
  • Indivior Plc
  • iX Biopharma Ltd
  • Novartis AG
  • Orexigen Therapeutics Inc
  • MORE
Introduction

Report Coverage

Opium (Opioid) Addiction - Overview

Opium (Opioid) Addiction - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Opium (Opioid) Addiction - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Opium (Opioid) Addiction - Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Aoxing Pharmaceutical Company Inc

BioCorRx Inc

BioDelivery Sciences International Inc

Camurus AB

Fab'entech SA

Indivior Plc

Insys Therapeutics Inc

iX Biopharma Ltd

Nemus Bioscience Inc

Novartis AG

Omeros Corp

Opiant Pharmaceuticals Inc

Orexigen Therapeutics Inc

Orexo AB

Pfizer Inc

Relmada Therapeutics Inc

Syntropharma Ltd

Titan Pharmaceuticals Inc

Zynerba Pharmaceuticals Inc

Opium (Opioid) Addiction - Drug Profiles

(buprenorphine + naloxone ) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(buprenorphine + naloxone) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

18-MC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADX-71441 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADX-88178 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANS-6637 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody for Poisoning, Drug Overdose and Opioid Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQU-010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPRX-060312 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine hydrochloride depot - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine MR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cannabidiol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Canquit-O - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FP-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mavoglurant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-1104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NB-2111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT-814 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-405 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-527 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPNT-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OREX-1019 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-4363467 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-5006739 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMZ-2123 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize D3 Receptor for Opioid Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target Calcium Activated Potassium Channel, KOR1, and MOR1 for Chronic pain and Opioid Dependence - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Opium Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Opium (Opioid) Addiction - Dormant Projects

Opium (Opioid) Addiction - Discontinued Products

Opium (Opioid) Addiction - Product Development Milestones

Featured News & Press Releases

Feb 13, 2018 : Heroin vaccine blocks lethal overdose

Feb 12, 2018 : BioCorRx Announces Results of Pre-IND meeting with FDA for Sustained Release Naltrexone Implant, BICX

Feb 08, 2018 : Indivior Files Complaints Asserting New SUBOXONE Film Patent Against ANDA-filers

Jan 22, 2018 : Titan In Discussions With Braeburn Regarding U.S. Probuphine Commercialization

Jan 21, 2018 : Braeburn Receives Complete Response Letter for CAM2038 Injectable Buprenorphine Depot

Jan 05, 2018 : BioCorRx Retains Regulatory Drug Expert Priya Jambhekar and CMC Expert Bruce Firestone

Jan 02, 2018 : BioCorRx CEO, Brady Granier, Appears on Fox & Friends to Discuss the Opioid Epidemic

Dec 19, 2017: BioCorRx Submits Pre-IND Package to FDA for its Naltrexone Implant, BICX

Dec 18, 2017: Opiant Pharma Announces Publication of New Pre-Clinical Data Supporting Potential of OPNT005 as a Heroin Vaccine

Dec 18, 2017: New Vaccine Technology Shows Promise as a Tool to Combat the Opioid Crisis

Nov 27, 2017: European Medicines Agency Accepts Titan Pharmaceuticals Marketing Authorization Application For Probuphine

Nov 20, 2017: Liberate Pain Management Introduces Suboxone Therapy and Other New Services

Nov 14, 2017: Opioid treatment drugs have similar outcomes once patients initiate treatment

Nov 07, 2017: Camurus to present at Jefferies 2017 London Healthcare Conference

Nov 01, 2017: Braeburn Announces FDA Advisory Committee Recommends Approval of CAM2038 Buprenorphine Depot for the Treatment of Opioid Use Disorder

Appendix

Methodology

Coverage

Secondary Research

Secondary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Opium (Opioid) Addiction, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Opium (Opioid) Addiction - Pipeline by Addex Therapeutics Ltd, H1 2018

Opium (Opioid) Addiction - Pipeline by Aoxing Pharmaceutical Company Inc, H1 2018

Opium (Opioid) Addiction - Pipeline by BioCorRx Inc, H1 2018

Opium (Opioid) Addiction - Pipeline by BioDelivery Sciences International Inc, H1 2018

Opium (Opioid) Addiction - Pipeline by Camurus AB, H1 2018

Opium (Opioid) Addiction - Pipeline by Fab'entech SA, H1 2018

Opium (Opioid) Addiction - Pipeline by Indivior Plc, H1 2018

Opium (Opioid) Addiction - Pipeline by Insys Therapeutics Inc, H1 2018

Opium (Opioid) Addiction - Pipeline by iX Biopharma Ltd, H1 2018

Opium (Opioid) Addiction - Pipeline by Nemus Bioscience Inc, H1 2018

Opium (Opioid) Addiction - Pipeline by Novartis AG, H1 2018

Opium (Opioid) Addiction - Pipeline by Omeros Corp, H1 2018

Opium (Opioid) Addiction - Pipeline by Opiant Pharmaceuticals Inc, H1 2018

Opium (Opioid) Addiction - Pipeline by Orexigen Therapeutics Inc, H1 2018

Opium (Opioid) Addiction - Pipeline by Orexo AB, H1 2018

Opium (Opioid) Addiction - Pipeline by Pfizer Inc, H1 2018

Opium (Opioid) Addiction - Pipeline by Relmada Therapeutics Inc, H1 2018

Opium (Opioid) Addiction - Pipeline by Syntropharma Ltd, H1 2018

Opium (Opioid) Addiction - Pipeline by Titan Pharmaceuticals Inc, H1 2018

Opium (Opioid) Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H1 2018

Opium (Opioid) Addiction - Dormant Projects, H1 2018

Opium (Opioid) Addiction - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Opium (Opioid) Addiction, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Addex Therapeutics Ltd
  • Aoxing Pharmaceutical Company Inc
  • BioCorRx Inc
  • BioDelivery Sciences International Inc
  • Camurus AB
  • Fab'entech SA
  • Indivior Plc
  • Insys Therapeutics Inc
  • iX Biopharma Ltd
  • Nemus Bioscience Inc
  • Novartis AG
  • Omeros Corp
  • Opiant Pharmaceuticals Inc
  • Orexigen Therapeutics Inc
  • Orexo AB
  • Pfizer Inc
  • Relmada Therapeutics Inc
  • Syntropharma Ltd
  • Titan Pharmaceuticals Inc
  • Zynerba Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll